Healthcare Services

Immunomodulator Market Industry Forecast Reflecting Growth To $327.94 Billion By 2030

May 29, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Immunomodulator Market’s Market Value Anticipated To Evolve From 2026 To 2030?

The immunomodulator market has experienced robust expansion over recent years. It is projected to grow from $237.02 billion in 2025 to $255.25 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.7%. The historical increase in the market size stems from factors such as the rising prevalence of autoimmune disorders, the expansion of oncology and transplant procedures, an increased application of corticosteroids and traditional immunosuppressants, the growing adoption of hospital-based immunotherapy, and an enhanced clinical understanding of immune pathways.

The immunomodulator market is projected to experience substantial expansion over the coming years. This market is set to reach $327.94 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.5%. This anticipated growth is driven by several factors, including the creation of new biologics and small molecule agents, an escalating need for immuno-oncology treatments, a heightened emphasis on specific and safer immunomodulators, the proliferation of home-based and outpatient care options, and broadening uses in nascent infectious and inflammatory conditions. Key trends during this period are expected to encompass the growing uptake of biologic and targeted immunotherapies, increased application of combined immunomodulatory regimens, a surging emphasis on individualized and precise immunotherapy, the wider utilization of immunomodulators in chronic and autoimmune ailments, and a greater transition towards outpatient and sustained immune management strategies.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15591&type=smp

What Core Drivers Are Transforming The Immunomodulator Market?

The expansion of chronic illnesses is anticipated to drive the immunomodulator market forward. These enduring medical conditions typically emerge progressively and continue for extended durations, often spanning years or a lifetime. The escalating prevalence of chronic diseases is attributable to various interlinked factors, including an aging demographic, lifestyle choices, genetic susceptibilities, and the availability and framework of healthcare systems. Immunomodulators offer crucial therapeutic avenues for addressing chronic diseases by adjusting immune reactions, diminishing inflammation, hindering organ rejection, bolstering immune oversight, and ameliorating symptom management. For example, in September 2023, the World Health Organization, a Switzerland-based specialized agency of the United Nations, reported 41 million deaths annually worldwide from non-communicable diseases (NCDs), also known as chronic diseases, which represents 74% of all deaths. Specifically, cardiovascular diseases accounted for 17.9 million deaths, cancer for 9.3 million deaths, chronic respiratory diseases for 4.1 million deaths, and diabetes for 2.0 million deaths. Consequently, the increasing incidence of chronic diseases is fueling the growth of the immunomodulator market.

How Does Segment Analysis Break Down The Immunomodulator Market Structure?

The immunomodulator market covered in this report is segmented –

1) By Product Type: Immunosuppressants, Immunostimulants, Other Product Types

2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels

3) By Application: Oncology, Respiratory, Human Immunodeficiency Virus, Other Applications

4) By End-User: Hospitals, Clinics, Other End Users

Subsegments:

1) By Immunosuppressants: Corticosteroids, Calcineurin Inhibitors (Tacrolimus, Cyclosporine), Mtor Inhibitors (Sirolimus, Everolimus), Antimetabolites ( Azathioprine, Methotrexate), Biologic Immunosuppressants (Monoclonal Antibodies Like Rituximab), Janus Kinase (Jak) Inhibitors, T-Cell Inhibitors, Other Immunosuppressive Agents

2) By Immunostimulants: Cytokine And Growth Factor-Based Immunostimulants ( Interferons, Interleukins), Monoclonal Antibodies For Immune Stimulation, Vaccines ( Cancer Vaccines, Preventive Vaccines), Adjuvants And Immune Modulatory Agents, Immunostimulatory Agents For Autoimmune Diseases, Toll-Like Receptor (Tlr) Agonists, Nucleic Acid-Based Immunostimulants ( Dna Or Rna Vaccines)

3) By Other Product Types: Biologics ( Fusion Proteins, Immune Checkpoint Inhibitors), Small Molecule Immunomodulators, Immunotherapy Drugs, Stem Cell-Based Immunomodulators, Immuno-Oncology Drugs, Probiotics And Other Natural Immunomodulatory Agents

What Trends Are Influencing The Future Of The Immunomodulator Market?

Leading companies in the immunomodulator market are focusing on developing non-immunosuppressive products to meet the rising demand for treatments that provide targeted immune modulation without impacting the body’s general immune function. Non-immunosuppressive refers to therapies or substances that do not suppress or diminish the immune system’s response. For instance, in February 2024, Nuvig Therapeutics, Inc., a US-based biotechnology company, began early-stage clinical trials for NVG-2089, a next-generation immune modulator. NVG-2089 is a proprietary product intended for patients with inflammatory myopathies and severe dermatologic autoimmune diseases. The FDA has granted fast-track designation for NVG-2089’s development specifically for bullous pemphigoid. This innovative, recombinant, non-immunosuppressive immunomodulator targets type II Fc receptors to activate an endogenous regulatory mechanism that reduces autoimmune dysregulation. The study’s main goal is to assess the safety and tolerability of NVG-2089, with secondary objectives focusing on its pharmacokinetics and pharmacodynamics.

Which Organizations Are Operating Within The Immunomodulator Market?

Major companies operating in the immunomodulator market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, AbbVie Inc., Sanofi S.A, Bristol Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., UCB S.A., Horizon Therapeutics plc, Incyte Corporation, Kyowa Kirin Co. Ltd.

Access The Complete Immunomodulator Market Report:

https://www.thebusinessresearchcompany.com/report/immunomodulator-global-market-report

Which Region Is The Dominant Market In The Immunomodulator Market?

North America was the largest region in the immunomodulator market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the immunomodulator market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Immunomodulator Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=15591&type=smp

Browse Through More Reports Similar to the Global Immunomodulator Market 2026, By The Business Research Company

Immunoassay Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/immunoassay-global-market-report

Immunotoxin Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/immunotoxin-global-market-report

Immunohematology Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/immunohematology-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795